07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Weill Cornell Medical College, Angiocrine Bioscience deal

Angiocrine licensed rights from the college to technology that converts patient's own endothelial cells into hematopoietic stem cells. Angiocrine will use the technology to produce hematopoietic cell grafts grown on Angiocrine's VeraVec endothelial cells, which...
08:00 , Dec 19, 2013 |  BC Innovations  |  Targets & Mechanisms

Balancing act in liver fibrosis

CXCR7 , one of the few chemokine receptors against which there are virtually no drug development efforts, may be a novel target for liver fibrosis, according to new findings from a U.S. team. 1 The...